TY - JOUR T1 - Complete regression of advanced HCC with long acting octreotide JF - Gut JO - Gut SP - 1531 LP - 1531 DO - 10.1136/gut.52.10.1531-a VL - 52 IS - 10 AU - J T Siveke AU - C Folwaczny AU - C Herberhold Y1 - 2003/10/01 UR - http://gut.bmj.com/content/52/10/1531.2.abstract N2 - Various therapeutic approaches for unresectable hepatocellular carcinoma (HCC) have been suggested in recent years. However, major advances concerning tumour regression or patient survival were not achieved. A few trials have assessed the effect of the somatostatin analogue octreotide in advanced HCC with divergent results.1,2 The latter might be due to expression of somatostatin receptor type 2 (SSTR2) in some but not all patients with HCC.3,4 Herein we describe a patient with advanced HCC who was treated with long acting octreotide, which resulted in complete and prolonged regression of the tumour.The patient was diagnosed with HCC after a suspect nodule … ER -